ATAI

Ataibeckley Inc.

A clinical-stage biopharmaceutical company developing psychedelic-inspired treatments for mental health, including BPL-003, a short-acting nasal spray for hard-to-treat depression. It was born in 2025 from the merger of atai Life Sciences and Beckley Psytech, the latter named after Beckley Park, the centuries-old English estate of the Feilding family. Its lead therapy is a synthetic form of a compound found in toad venom.